BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression | Journal for ImmunoTherapy of Cancer

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression

Online download statistics by month:

Online download statistics by month: September 2022 to March 2024

	Abstract	Full	Pdf
Sep 2022	1176	1197	331
Oct 2022	560	569	158
Nov 2022	399	400	248
Dec 2022	263	268	105
Jan 2023	377	379	131
Feb 2023	333	336	149
Mar 2023	310	314	118
Apr 2023	210	211	92
May 2023	231	232	115
Jun 2023	244	248	102
Jul 2023	328	329	130
Aug 2023	330	333	99
Sep 2023	225	226	73
Oct 2023	187	187	72
Nov 2023	239	241	109
Dec 2023	236	237	66
Jan 2024	163	164	68
Feb 2024	170	171	58
Mar 2024	231	232	104
Total	6212	6274	2328